Improved depth of response with increased follow-up in phase 1 trial of patients with Waldenström macroglobulinemia (WM) treated with oral Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111)

Constantine S. Tam,^{1,2,3,4} Judith Trotman,^{5,6} Paula Marlton,^{7,8} David Gottlieb,⁹ David Simpson,¹⁰ Gavin Cull,^{11,12} David Ritchie,^{1,2} Emma Verner,⁵ Javier Munoz,¹³ Sumita Ratnasingam, ¹⁴ Mary Ann Anderson,^{1,6} Peter Wood,^{7,8} Eric Hedrick,¹⁵ Jane Huang,¹⁵ Sunhee Ro,¹⁵ James Hilger,¹⁵ John F. Seymour,^{1,2} Andrew W. Roberts,^{2,4} and Stephen Opat^{14,16}

¹Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia; ²University of Melbourne, Parkville, Victoria, Australia; ³St Vincent's Hospital, Fitzroy, Victoria, Australia; ⁴Royal Melbourne Hospital, Parkville, Victoria, Australia; ⁵Concord Repatriation General Hospital, Concord, Australia; ⁶University of Sydney, Concord, Australia; ⁷Princess Alexandra Hospital, Brisbane, Australia; ⁸University of Queensland, Brisbane, Australia; ⁹University of Sydney, Westmead Hospital, Sydney, Australia; ¹⁰ North Shore Hospital, Auckland, New Zealand; ¹¹ Sir Charles Gairdner Hospital, Perth, Western Australia; Australia; ¹²University of Western Australia; Perth, Australia. ¹³Banner MD Anderson Cancer Center, Gilbert, AZ, USA; ¹⁴Monash Health, Clayton, Victoria, Australia; ¹⁵BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, USA; ¹⁶Monash University, Clayton, Victoria, Australia

Disclosures

• I receive honoraria and research funding from Beigene, Janssen and AbbVie.

Introduction

- Bruton's tyrosine kinase (BTK) plays a critical role in B-cell receptor signaling, which mediates B-cell proliferation, migration, and adhesion^{1–3}
 - BTK is constitutively activated in WM and is a key mediator in cell survival^{4,5}
- First-generation BTK inhibitor Ibrutinib has shown activity in WM and become a standard of care^{6,7}
 - Major response rate: 73% (including 16% very good partial response)⁸
 - -68% 3-year event-free survival9


Rickert RC. *Nat Rev Immunol.* 2013;13:578-591.
 Choe H, Ruan J. *Oncology* (Williston Park). 2016;30:847-858.
 Aalipour A, Advani RH. *Br J Haematol.* 2013;163:436-443.
 Treon SP, et al. *Blood.* 2014;123:2791-2796.;
 Argyropoulos KV, et al. *Leukemia.* 2016;30:1116-1125.
 IMBRUVICA[®] (ibrutinib). Full Prescribing Information. February 2018.
 IMBRUVICA[®] (ibrutinib). Summary of Product Characteristics. February 2018.
 Treon SP, et al. *N Engl J Med.* 2015;372:1430-1440.
 Palomba ML, et al. IWWM. 2016 [abstract].

Zanubrutinib - kinase selectivity relative to ibrutinib

.	Targets	Assays	Zanubrutinib ¹ IC ₅₀ (nM)	lbrutinib ¹ IC ₅₀ (nM)	Ratio (Zanubrutinib:Ibrutinib)
RGET	ВТК	BTK-pY223 Cellular Assay	1.8	3.5	0.5
		Rec-1 Proliferation	0.36	0.34	1.1
TA		BTK Occupation Cellular Assay	2.2	2.3	1.0
NO		BTK Biochemical Assay	0.22	0.2	1.1

	EGFR	p-EGFR HTRF Cellular Assay	606	101	6
OFF TARGET	EGFK	A431 Proliferation	3210	323	9.9
	ITK	ITK Occupancy Cellular Assay	606	189	17
		p-PLC _{γ1} Cellular Assay	3433	77	45
		IL-2 Production Cellular Assay	2536	260	9.8
		ITK Biochemical Assay	30	0.9	33
	JAK3	JAK3 Biochemical Assay	200	3.9	51
	HER2	HER2 Biochemical Assay	661	9.4	70
	TEC	TEC Biochemical Assay	1.9	0.8	2.4

Pharmacokinetics of zanubrutinib, ibrutinib, and acalabrutinib




Note: these data are from 3 separate analyses and differences in studies should be considered.

1. Tam CS, et al. Blood. 2015;126:832 [oral presentation].

2. Advani RH, et al. J Clin Oncol. 2013;31:88-94.

3. Byrd JC, et al. N Engl J Med. 2016;374:323-332.

Sustained BTK inhibition in peripheral blood and lymph nodes



Complete and sustained BTK occupancy is seen in paired PBMC (left figure) and lymph node biopsy samples (right figure) collected pre-dose on day 3. In blood samples, complete BTK occupancy was seen at the lowest dose (40 mg). Note, 100% median trough occupancy at a dose of 160 mg bid with 94% of patients having >90% occupancy in lymph nodes across malignancies.

Objective

 Presented here are updated results from patients with WM treated within an ongoing phase 1 zanubrutinib trial (NCT02343120)

Trial design (NCT02343120)

DOSE ESCALATON		RP2D	DOSE EXPANSION			
Dose	Enrolled	Dose	Population	RP2D Dose	Disease	Enrolled [†] (WM)
	(WM)	320 mg QD	R/R	BID or QD	All B-cell	40 (2)
40 mg QD	4 (1)	160 mg BID	R/R	BID	Non-GCB DLBCL	40
80 mg QD	5 (2)		R/R	BID	CLL/SLL	70
160 mg QD	6 (1)	Both doses	R/R	BID	WM	20 (21)
		RP2D but as of	R/R	QD	CLL/SLL	20
320 mg QD	6 (0)	protocol v.6 all pts encouraged	R/R or TN	BID or QD	WM	50 (50)
160 mg BID	4 (0)	to switch to 160	R/R	BID or QD	MCL	20
		mg BID	TN	BID or QD	CLL/SLL	20
			TN	BID or QD	MCL	20
Cohorts containing		R/R	BID or QD	HCL	10	
[†] Enrollment in expansion as of data cutoff noted in	ollment shown, with WM enrollment	R/R	BID	iNHL	40	
BID, twice daily; CLL/SLL	ukemia/small lymphocytic	R/R	BID	Richter's	15	

R/R (prior BTK)

BID


All B-cell

BID, twice daily; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; GCB, germinal center B-cell–like; HCL, hairy cell leukemia; iNHL, indolent non-Hodgkin lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; RP2D, recommended phase 2 dose; QD, once daily; WM, Waldenström macroglobulinemia

15

Methods

- First-in-human, open-label, multicenter, phase 1 study of zanubrutinib in patients with B-cell malignancies
- Eligibility
 - WHO-defined B-cell malignancy with no available higher priority treatment
 - Eastern Cooperative Oncology Group 0-2
 - ANC ≥1000/µL, platelets ≥50000/µL (growth factor/transfusions allowed)
 - Adequate renal and hepatic function
 - No significant cardiac disease (anticoagulation allowed)
- Primary endpoints
 - Safety including AEs and SAEs per the NCI CTCAE v4.03, based on physical examination and laboratory measurements
 - Recommended phase 2 dose
- Select secondary endpoints
 - Pharmacokinetics
 - Efficacy, including overall response rate, progression-free survival, overall survival, and duration of response



Patient and disease characteristics

Data cut 24-JULY-2018

Characteristic	Total (N=77)
Age, years, median (range)	67 (40-87)
ECOG performance status, n (%) 0 1 2	27 (35.1) 47 (61) 3 (3.9)
Prior treatment status Treatment-naïve, n (%) Relapsed/refractory (R/R), n (%) Number of prior therapies for R/R patients, median (range)	24 (31.2) 53 (68.8) 2 (1-8)
Genotype, n (%) MYD88 ^{L265P} /CXCR4 ^{WT} MYD88 ^{L265P} /CXCR4 ^{WHIM} MYD88 ^{WT} Unavailable	49 (63.6) 6 (7.8) 12 (15.6) 10 (13)

ECOG, Eastern Cooperative Oncology Group.

Adverse events overview

Data cut 24-JULY-2018


Event	n (%)		
Patients with ≥1 AE Grade ≥3	39 (50.6)		
Patients with ≥1 serious AE*	32 (41.6)		
AE leading to treatment discontinuation	9 [†] (11.7)		
Fatal AE	5 [‡] (6.5)		
AE of special interest			
Petechiae/purpura/contusion	33 (42.9)		
Diarrhea	13 (16.9)		
Hypertension	9 (11.7)		
Major hemorrhage [§]	2 (2.6)		
Atrial fibrillation/flutter	4 (5.2)		

*SAEs possibly related to zanubrutinib (n=5): hemothorax, atrial fibrillation, colitis, febrile neutropenia, and pneumonia (each n=1).
*Abdominal sepsis (fatal), septic shoulder, worsening bronchiectasis, scedosporium infection, gastric adenocarcinoma (fatal), prostate adenocarcinoma, metastatic neuroendocrine carcinoma, acute myeloid leukemia, breast cancer (each n=1, all unrelated).
*Septic shoulder, worsening bronchiectasis, abdominal sepsis + appendicitis + renal failure, gastric adenocarcinoma, scedosporium infection: all unrelated.

[§]Defined as any grade ≥3 hemorrhage or any grade CNS hemorrhage, gastrointestinal hemorrhage, hematuria, renal hematoma: one pt had G3 hemothorax and Melena, one pt had G3 hemorrhagic cystitis.

Common adverse events (>10%), G3-4 adverse (n≥3), and BTK-i events of interest, regardless of causality

Data cut 24-JULY-2018



^aGrade \geq 3 hemorrhage, or CNS hemorrhage of any grade.

Best overall response

Best response, n (%)	All Efficacy Evaluable (n=73)	TN Patients (n=24)	R/R Patients (n=49)			
ORR	67 (91.8)	23 (95.8)	44 (89.8)			
MRR	60 (82.2)	21 (87.5)	39 (79.6)			
VGPR	30 (41.1)	6 (25.0)	24 (49.0)			
PR	30 (41.1)	15 (62.5)	15 (30.6)			
MR	7 (9.6)	2 (8.3)	5 (10.2)			
SD	5 (6.8)	1 (4.2)	4 (8.2)			
PD	1 (1.4)	0 (0)	1 (2.0)			
Time to response (≥PR), median (range)						
Days	85 (55-749)	87 (55-693)	85 (56-749)			

Median follow-up: 22.5 mo (4.1-43.9) - 10.6 mo for TN, 23.1 mo for R/R

MR, minor response; PD, progressive disease; PR, partial response; SD, stable disease; VGPR, very good partial response.

Best overall response by MYD88 mutation status


Data cut 24-JULY-2018

Rost rosponso	All Efficacy	MYDa	MYD88 ^{wt}	
Best response, n (%)	Evaluable (n=73)	<i>СХСR4^{wт}</i> (n=48)	<i>CXCR4^{wнiм}</i> (n=6)	(n=9)
ORR	67 (91.8)	45 (93.8)	6 (100)	8 (88.9)
MRR	60 (82.2)	42 (87.5)	6 (100)	6 (66.7)
VGPR	30 (41.1)	23 (47.9)	2 (33.3)	2 (22.2)
PR	30 (41.1)	19 (39.6)	4 (66.7)	4 (44.4)
MR	7 (9.6)	3 (6.3)	0	2 (22.2)
SD	5 (6.8)	3 (6.3)	0	1 (11.1)
PD	1 (1.4)	0	0	0

MR, minor response; PD, progressive disease; PR, partial response; SD, stable disease; VGPR, very good partial response.


Best response over time in patients with ≥1 year of follow-up (n=46)

Data cut 24-JULY-2018



MR, minor response; PR, partial response; SD, stable disease; VGPR, very good partial response.

Hemoglobin and IgM over time in evaluable patients (n=73)




Shaded areas show the error bars associated with each assessment.

Median IgM decreased from 32.7 g/L (range, 5.3-91.9) at baseline to 8.2 g/L (range, 0.3-57.8).

Of 32 patients with hemoglobin <10 g/dL at baseline, the median increased from 8.85 g/dL (range, 6.3-9.8) to 13.4 g/dL (range, 7.7-17.0).

Progression-free survival in evaluable patients through 36 months (n=73)

Data cut 24-JULY-2018



Shaded area shows the 95% CI.

Conclusions

- Zanubrutinib, an investigational, highly selective oral BTK inhibitor showed high plasma concentrations and complete sustained BTK occupancy in blood and lymph nodes
- Updated results from an ongoing phase 1 trial in patients with B-cell malignancies suggest that zanubrutinib was generally well-tolerated and highly active in patients with WM
 - Overall response rate of 92% including 41% with VGPR
 - Increased depth of response over time
 - Estimated 12 month PFS of 89%
 - Discontinuation due to AEs occurred in 11.7% of patients and was determined not to be related to zanubrutinib treatment
- A phase 3 trial comparing zanubrutinib with ibrutinib in patients with WM is ongoing

Acknowledgments

- We would like to thank the investigators, site support staff, and especially the patients for participating in this study
- This study was sponsored by BeiGene. Editorial support was provided by Bio Connections and funded by BeiGene

Back-Up

Best overall response by MYD88 mutation status

Data cut 24-JULY-2018

Best	All Efficacy				Unknown Status
response, n (%)	Evaluable (n=73)	<i>СХСR4^{wт}</i> (n=48)	<i>CXCR4^{wнім}</i> (n=6)	(n=9)	(n=10)
ORR	67 (91.8)	45 (93.8)	6 (100)	8 (88.9)	8 (80)
MRR	60 (82.2)	42 (87.5)	6 (100)	6 (66.7)	6 (60)
VGPR	30 (41.1)	23 (47.9)	2 (33.3)	2 (22.2)	3 (30)
PR	30 (41.1)	19 (39.6)	4 (66.7)	4 (44.4)	3 (30)
MR	7 (9.6)	3 (6.3)	0	2 (22.2)	2 (20)
SD	5 (6.8)	3 (6.3)	0	1 (11.1)	1 (10)
PD	1 (1.4)	0	0	0	1 (10)

Median follow-up: 22.5 mo (4.1-43.9)

MR, minor response; PD, progressive disease; PR, partial response; SD, stable disease; VGPR, very good partial response.